Abstract
Background
The impact of postoperative radiotherapy (PORT) on outcomes has been a matter of debate after adequate resection in Ewing’s sarcoma of the pelvis. We evaluated our cases after surgical excision in pelvic Ewing’s sarcoma and assessed local control and overall survival (OS) with respect to PORT and chemotherapy-induced percentage necrosis.
Materials and Methods
Forty four surgically operated patients (June 2002–November 2014) of localized Ewing’s sarcoma were retrospectively reviewed. There were 31 males and 13 females. Age ranged from 2 to 53 years. All patients received institutional chemotherapy protocol. No patient received preoperative radiotherapy. Specimen was analyzed for margins and chemotherapy-induced percentage necrosis. PORT was offered to patients on case-by-case basis. Presence of a large preoperative soft-tissue component, margin evaluation, and percentage necrosis were factors considered. At time of the last followup, 29 patients were alive, 11 died, and 4 were lost to followup. Survivors had a minimum followup of 2 years (range: 31–118 months, mean = 69 months).
Results
One of twenty (5%) patients with PORT had a local recurrence as against 2 of 24 (8%) without PORT. OS of all patients was 76% at 5 years. Twelve patients with <90% necrosis had OS of 56% and 32 with >90% necrosis had OS of 83% (P = 0.040). OS of patients with PORT was 74%, without PORT was 78% (P = 0.629).
Conclusions
The decision to offer PORT after surgical excision in pelvic Ewing’s sarcoma is multifactorial; the absence of PORT in selected cases is not detrimental to local control. Poor responders to chemotherapy had poorer survival while PORT did not impact on outcomes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DuBois SG, Krailo MD, Gebhardt MC, Donaldson SS, Marcus KJ, Dormans J, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children’s Oncology Group. Cancer 2015;121:467–75.
Biswas B, Rastogi S, Khan SA, Mohanti BK, Sharma DN, Sharma MC, et al. Outcomes and prognostic factors for Ewing-family tumors of the extremities. J Bone Joint Surg Am 2014;96:841–9.
ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2014;25 Suppl 3:iiil 13–23.
Schuck A, Ahrens S, Paulussen M, Kuhlen M, Könemann S, Rübe C, et al. Local therapy in localized Ewing tumors: Results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003;55:168–77.
Indelicate DJ, Keole SR, Shahlaee AH, Shi W, Morris CG, Marcus RB Jr., et al. Definitive radiotherapy for ewing tumors of extremities and pelvis: Long term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys 2008;72:871–7.
Sultan I, Rihani R, Hazin R, Rodriguez-Galindo C. Second malignancies in patients with Ewing sarcoma family of tumors: A population-based study. Acta Oncol 2010;49:237–44.
Ahmed SK, Robinson SI, Arndt CAS, Petersen IA, Haddock MG, Rose PS, et al. Pelvis Ewing sarcoma: Local control and survival in the modern era. Pediatr Blood Cancer 2017;64:e26504.
Foulon S, Brennan B, Gaspar N, Dirksen U, Jeys L, Cassoni A, et al. Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. Eur J Cancer 2016;61:128–36.
Bacci G, Forni C, Longhi A, Ferrari S, Donati D, De Paolis M, et al. Long term outcome for patients with non-metastatic Ewing’s sarcoma treated with adjuvant and neoadjuvant chemotherapies 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004;40:73–83.
Rodríguez-Galindo C, Navid F, Liu T, Billups CA, Rao BN, Krasin MJ, et al. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol 2008;19:814–20.
Puri A, Gulia A, Jambhekar NA, Laskar S. Results of surgical resection in pelvic Ewing’s sarcoma. J Surg Oncol 2012;106:417–22.
Fuchs B, Valenzuela RG, Sim FH. Pathologic fracture as a complication in the treatment of Ewing’s sarcoma. Clin Orthop Relat Res 2003;415:25–30.
Indelicate DJ, Keole SR, Shahlaee AH, Shi W, Morris CG, Gibbs CP Jr., et al. Impact of local management on long term outcomes in Ewing tumors of the pelvis and sacral bones: The University of Florida experience. Int J Radiat Oncol Biol Phys 2008;72:41–8.
Dramis A, Grimer RJ, Malizos K, Tillman RM, Jeys L, Carter LR, et al. Non-Metastatic Pelvic Ewing’s Sarcoma: Oncologic outcomes and evaluation of prognostic factors. Acta Orthop Belg 2016;82:216–21.
Stahl M, Ranft A, Paulussen M, Boiling T, Vieth V, Bielack S, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011;57:549–53.
Carrie C, Mascard E, Gomez F, Habrand JL, Alapetite C, Oberlin O, et al. Nonmetastatic pelvic Ewing sarcoma: Report of the French society of pediatric oncology. Med Pediatr Oncol 1999;33:444–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Puri, A., Gulia, A., Crasto, S. et al. Does Radiotherapy after Surgery Affect Outcomes in Ewing’s Sarcoma of the Pelvis?. IJOO 52, 73–76 (2018). https://doi.org/10.4103/ortho.IJOrtho_388_17
Published:
Issue Date:
DOI: https://doi.org/10.4103/ortho.IJOrtho_388_17